More ADCs. More Competition.
More Pressure to Differentiate.
ADC development has entered a new phase. The challenge is no longer proving the modality works, but improving safety, overcoming resistance, identifying differentiated targets, and standing out in an increasingly competitive market.
This review brings together the data, trends, and market signals that matter most. Discover how the landscape has evolved with 400 new ADC assets since January, why bispecific ADCs now account for 55% of all novel ADCs, and what $26 billion in ADC deal value reveals about the technologies and drugs attracting investment.
Whether you’re evaluating targets, tracking emerging technologies, assessing partnering opportunities, or planning future R&D investments, this report provides valuable foresight into where the ADC market is heading next.
What’s Inside?
The Drug Landscape
Explore the 2,689-asset ADC landscape, including emerging modalities, target trends, payload innovation, and the growing role of bispecific and dual-payload ADCs.
The Trial Landscape
Analyze clinical activity across 3,397 trials, including phase transitions, first-in-human studies, recruiting trends, and notable discontinuations.
The Commercial Landscape
Identify where investment, partnering activity, and strategic interest are concentrated across 75 ADC deals worth $26B in disclosed value.
Regulatory Announcements
Track 417 regulatory updates, including approvals, submissions, designations, and key milestones from across the global ADC market.
Patent Landscape
Discover where innovation is accelerating through analysis of 7,180 patent family publications, leading assignees, and emerging targets.
The Future of ADCs
See how developers are pursuing differentiation through next-generation formats, novel payloads, and advanced engineering strategies.
Previous ADC Landscape Reviews
ADC 2025 Landscape Review
ADC H1 2025 Landscape Review
ADC 2024 Landscape Review
You May Also Be Interested In…
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
